



final

GYNECOLOGIC CANCER INTERGROUP (GCIG) QUALITY ASSURANCE WORKING GROUP

THURSDAY, OCTOBER 27, 2016, 4:30PM – 5:30PM

AUGUSTA II ROOM, DoubleTree Fontana Hotel, Lisbon

Chair: J. Bryce Co-Chair: A. Brand

AGENDA

Welcome & Introductions:

COI declarations:

Members: J.Bryce, Chair (MITO), C.Marth (AGO-Au), AC Hardy (GINECO), D. O'Donnell (ICORG), B.Stonebraker (GOG), O. Dorigo (COGi), S. Polleis (AGO), R. Berger (AGO-Au), B. Sapetto-Rebow (ICORG), B. Choi (KGOG), L. Farrelly (MRC-NCRI), K. Carty (SGCTG), A. Chavez (GICOM), M. Keller (NOGGO), M.Huizing (BGOG), H.Nijman (DGOG), A.Brand (ANZGOG), R. Fossati (MaNGO), Xiaojun Chen (SGOG), S. Pilat (G-GOC), A Hiltz (CCTG), N Ottevanger (EORTC) E Ronnengart (NSGO), C Blattler (PMHC), J.Vermorken (Exec.),

MINUTES/REPORT: June 2016 (posted)

Motion: _____ Seconded: _____

GCIG Trial Badging: Bryce, Brand

GCP addendum update: A. Negrouk

Autumn 2017 QA day planning

1. What should be minimum stds of QA for GCIG ?
2. What are some persistent regulatory issues that impact quality in GCIG trials?

Monitoring / Auditing / network / panel M. Bacon

ADJOURN